标准治疗复发难治多发性骨髓瘤接受艾基奥仑赛后的心脏事件
这项回顾性单中心观察研究纳入78例接受标准治疗艾基奥仑赛的复发难治多发性骨髓瘤患者,11例(14.1%)发生心脏事件,包括心力衰竭5.1%、心房颤动10.3%、非持续性室性心动过速3.8%和心血管死亡1.3%。基线体能状态差以及高级别细胞因子释放综合征和免疫细胞相关神经综合征与心脏事件相关;多变量分析中心脏事件与总生存的风险比为2.66、与无进展生存的风险比为1.98。作者认为心脏事件可能伴随更差的无进展生存或总生存,但样本量小导致检测关联的效能有限。
要点
- 78例接受艾基奥仑赛的患者中11例(14.1%)发生心脏事件,中心力衰竭5.1%、心房颤动10.3%。
- 基线女性、体能状态差、λ轻链疾病和晚期R-ISS分期与心脏事件发生相关。
- CAR-T后住院期间≥2级细胞因子释放综合征和免疫细胞相关神经综合征与心脏事件相关。
核心结论
- 艾基奥仑赛治疗复发难治多发性骨髓瘤的心脏事件与其他类型CAR-T相似。
- 基线体能状态差及更高级别细胞因子释放综合征和神经毒性与BCMA靶向CAR-T后心脏事件相关。
- 作者认为心脏事件可能伴随更差的无进展生存或总生存,但因样本量小检测关联的效能有限。
研究设计与样本
- 回顾性单中心观察研究,纳入所有接受标准治疗艾基奥仑赛且至少随访1个月的连续复发难治多发性骨髓瘤患者,共78例。
主要发现
- 78例中11例(14.1%)发生心脏事件:心力衰竭5.1%、心房颤动10.3%、非持续性室性心动过速3.8%、心血管死亡1.3%。
- 78例中仅11例复查了超声心动图。
- 与心脏事件发生相关的基线危险因素包括女性、体能状态差、λ轻链疾病和晚期修订版国际分期系统分期。
- 基线心脏特征与心脏事件无关联。
- CAR-T后住院期间,≥2级细胞因子释放综合征和免疫细胞相关神经综合征与心脏事件相关。
局限性
- 作者指出因样本量小,检测心脏事件与生存关联的效能有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Idecabtagene vicleucel (ide-cel) is a type of B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor T-cell (CAR-T) approved for the treatment of relapsed and refractory multiple myeloma (RRMM). Currently, the incidence of cardiac events associated with ide-cel remains unclear. This was a retrospective single-center observational study of patients treated with ide-cel for RRMM. We included all consecutive patients who received standard-of-care ide-cel treatment at least 1-month follow-up. Baseline clinical risk factors, safety profile, and responses were examined based on the development of a cardiac event. A total of 78 patients were treated with ide-cel, and 11 patients (14.1%) developed cardiac events: heart failure (5.1%), atrial fibrillation (10.3%), nonsustained ventricular tachycardia (3.8%), and cardiovascular death (1.3%). Only 11 of the 78 patients had repeat echocardiogram. Baseline risk factors associated with the development of cardiac events included being female sex and having poor performance status, λ light-chain disease, and advanced Revised International Staging System stage. Baseline cardiac characteristics were not associated with cardiac events. During index hospitalization after CAR-T, higher-grade (≥grade 2) cytokine release syndrome (CRS) and immune cell-associated neurologic syndrome were associated with cardiac events. In multivariable analyses, the hazard ratio for the association of the presence of cardiac events with overall survival (OS) was 2.66 and progression-free survival (PFS) was 1.98. Ide-cel CAR-T for RRMM was associated with similar cardiac events as other types of CAR-T. Worse baseline performance status and higher-grade CRS and neurotoxicity were associated with cardiac events after BCMA-directed CAR-T-cell therapy. Our results suggest that the presence of cardiac events may confer worse PFS or OS; although because of the small sample size, the power to detect an association was limited.
引用
- Lee DH, Kumar A, Mohammed T, et al. Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma. Blood Adv. 2023. PMID: 37307173. doi:10.1182/bloodadvances.2023009766
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。